Published in Arthritis Rheum on November 01, 2013
Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics J (2014) 0.96
Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther (2014) 0.87
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol (2016) 0.80
1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity (2014) 0.77
Drug therapy. Methotrexate normalizes folate pathway genes in RA. Nat Rev Rheumatol (2013) 0.75
Impaired NFKBIE gene function decreases cellular uptake of methotrexate by down-regulating SLC19A1 expression in a human rheumatoid arthritis cell line. Mod Rheumatol (2016) 0.75
Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum (2004) 7.79
Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum (2004) 7.13
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med (2006) 3.80
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood (2008) 3.65
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.26
Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum (2003) 3.05
Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS (2003) 2.78
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA (2011) 2.73
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis (2007) 2.67
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum (2009) 2.55
Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol (2002) 2.42
Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.35
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther (2006) 2.28
Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum (2004) 2.25
ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol (2012) 2.14
Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis (2011) 2.11
Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum (2005) 2.01
Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum (2004) 1.94
Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum (2003) 1.92
Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum (2008) 1.86
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis (2010) 1.81
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80
Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al. Arthritis Rheum (2006) 1.79
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum (2009) 1.77
Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum (2010) 1.77
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77
Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm (2010) 1.75
Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol (2008) 1.75
Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis (2011) 1.62
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood (2010) 1.62
Effects of dependence in high-dimensional multiple testing problems. BMC Bioinformatics (2008) 1.59
A multicentre study on the reliability of qualitative and quantitative nail-fold videocapillaroscopy assessment. Rheumatology (Oxford) (2011) 1.57
Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum (2013) 1.54
Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum (2007) 1.52
Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat (2011) 1.51
Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial. Ann Intern Med (2016) 1.51
Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. Arthritis Rheum (2005) 1.49
Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum (2012) 1.48
Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int (2009) 1.47
Avoidance of activities in early symptomatic knee osteoarthritis: results from the CHECK cohort. Ann Behav Med (2012) 1.46
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One (2008) 1.43
Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study. J Rheumatol (2012) 1.42
Different type of carotid arterial wall remodeling in rheumatoid arthritis compared with healthy subjects: a case-control study. J Rheumatol (2012) 1.40
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res (2011) 1.40
The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol (2003) 1.39
Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum (2011) 1.39
Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat (2012) 1.37
Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis (2013) 1.37
Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer (2003) 1.33
The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis (2010) 1.31
Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis (2012) 1.30
Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum (2012) 1.30
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis (2009) 1.29
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther (2012) 1.29
Functional disability in relation to radiological damage and disease activity in patients with rheumatoid arthritis in remission. J Rheumatol (2002) 1.29
Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development. Proc Natl Acad Sci U S A (2007) 1.29
Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis Rheum (2003) 1.28
Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum (2010) 1.28
Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood (2008) 1.28
Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum (2010) 1.27
Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol (2003) 1.27
Nonparametric testing for DNA copy number induced differential mRNA gene expression. Biometrics (2008) 1.27
Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther (2010) 1.26
High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. J Rheumatol (2008) 1.24
A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet (2011) 1.24
Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol (2005) 1.22
Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. Radiology (2002) 1.20
Osteoimmunology and osteoporosis. Arthritis Res Ther (2011) 1.20
Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem (2004) 1.19
Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Hum Mol Genet (2012) 1.17
Effect of redox balance alterations on cellular localization of LAT and downstream T-cell receptor signaling pathways. Mol Cell Biol (2002) 1.17
Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol (2010) 1.16
TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut (2011) 1.15